Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2015

Open Access 01-12-2015 | Research article

The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria

Authors: Ilir Agalliu, Akin O Adebiyi, David W Lounsbury, Oluwafemi Popoola, Kola Jinadu, Olukemi Amodu, Suvam Paul, Adebola Adedimeji, Chioma Asuzu, Michael Asuzu, Olufemi J Ogunbiyi, Thomas Rohan, Olayiwola B Shittu

Published in: BMC Public Health | Issue 1/2015

Login to get access

Abstract

Background

Men of African descent have the highest incidence and mortality rates of prostate cancer (PrCa) worldwide. Notably, PrCa is increasing in Africa with Nigerian men being mostly affected. Thus, it is important to understand risk factors for PrCa in Nigeria and build capacity for cancer research. The goals of this study were to determine the feasibility of conducting an epidemiological study of PrCa and to obtain preliminary data on risk factors for PrCa in Nigeria.

Methods

A case–control study (50 cases/50 controls) was conducted at the University College Hospital (UCH) in Ibadan, Nigeria, between October 2011 and December 2012. Men aged 40 to 80 years were approached for the study and asked to provide informed consent and complete the research protocol. Logistic regression models were used to examine associations between demographic, social and lifestyle characteristics and risk of PrCa.

Results

The participation rate among cases and controls was 98% and 93%, respectively. All participants completed a questionnaire and 99% (50 cases/49 controls) provided blood samples. Cases had a median serum diagnostic PSA of 73 ng/ml, and 38% had a Gleason score 8–10 tumor. Family history of PrCa was associated with a 4.9-fold increased risk of PrCa (95% CI 1.0 - 24.8). There were statistically significant inverse associations between PrCa and height, weight and waist circumference, but there was no association with body mass index (kg/m2). There were no associations between other socio-demographic and lifestyle characteristics and PrCa risk.

Conclusion

This feasibility study demonstrated the ability to ascertain and recruit participants at UCH and collect epidemiological, clinical and biospecimen data. Our results highlighted the advanced clinical characteristics of PrCa in Nigerian men, and that family history of PrCa and some anthropometric factors were associated with PrCa risk in this population. However, larger studies are needed to better understand the epidemiological risk factors of PrCa in Nigeria.
Literature
1.
American Cancer Society (ACS). Cancer Facts & Figures 2014. Atlanta, GA: ACS; 2014.
2.
Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute; 2014. http://​seer.​cancer.​gov/​csr/​1975_​2011/​, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
3.
4.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.CrossRefPubMed
5.
6.
Quinn M, Babb P. Patterns and Trends in Prostate Cancer Incidence, Survival, Prevalence and Mortality. Part I: International Comparisons. BJU Int. 2002;90(2):162–73.CrossRefPubMed
7.
Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4 Suppl 1:S2.CrossRefPubMedPubMedCentral
8.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
9.
Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer. 2013;2013:560857.CrossRefPubMedPubMedCentral
10.
Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107(5):797–803.CrossRefPubMed
11.
Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 2003;97(8):1894–903.CrossRefPubMed
12.
13.
14.
15.
Kristal AR, Cohen JH, Qu P, Stanford JL. Associations of Energy, Fat, Calcium, and Vitamin D With Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2002;11(8):719–25.PubMed
16.
Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J Urol. 2004;171:S19–24.CrossRefPubMed
17.
Chan JM, Giovannucci EL. Dairy Products, Calcium, and Vitamin D and Risk of Prostate Cancer. Epidemiol Rev. 2001;23(1):87–92.CrossRefPubMed
18.
Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol. 2005;23(32):8152–60.CrossRefPubMed
19.
Agalliu I, Kirsh VA, Kreiger N, Soskolne CL, Rohan TE. Oxidative balance score and risk of prostate cancer: Results from a case-cohort study. Cancer Epidemiol. 2011;35(4):353–61. doi: 10.1016/j.canep.2010.11.002.CrossRefPubMed
20.
MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17:989–1003.CrossRefPubMed
21.
22.
Rohrmann S, Genkinger JM, Burke A, Helzlsouer KJ, Comstock GW, Alberg AJ, et al. Smoking and Risk of Fatal Prostate Cancer in a Prospective U.S. Study. Urology. 2007;69(4):721–5.CrossRefPubMedPubMedCentral
23.
Pak RW, Lanteri VJ, Scheuch JR, Sawczuk IS. Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial. Integr Cancer Ther. 2002;1(4):338–44.CrossRefPubMed
24.
Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer. 2002;42:1–9.CrossRefPubMed
25.
Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev. 2004;13:340–5.PubMed
26.
Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control. 2005;16(9):1125–31.CrossRefPubMed
27.
Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006;98(4):245–54.CrossRefPubMed
28.
Tang D, Liu JJ, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, et al. Grilled Meat Consumption and Phip-Dna Adducts in Prostate Carcinogenesis. Cancer Epidemiol Biomark Prev. 2007;16(4):803–8.CrossRef
29.
Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007;29:88–97.CrossRefPubMed
30.
Hsing AW, Sakoda LC, Chua Jr S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86(3):s843–57.PubMed
31.
Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis. 2011;32(8):1107–21.CrossRefPubMedPubMedCentral
32.
Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol. 2013;25(3):235–41.PubMed
33.
Powell IJ, Bollig-Fischer A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol. 2013;27(6):879–91.CrossRefPubMed
34.
International Agency for Research on Cancer (IARC). World Cancer Report 2014. 1st ed. Lyon, France: International Agency for Research on Cancer (IARC); 2014.
35.
International Agency for Research on Cancer (IARC). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Geneva: World Health Organization; 2012.
36.
37.
Ekwere PD, Egbe SN. The changing pattern of prostate cancer in Nigerians: current status in the southeastern states. J Natl Med Assoc. 2002;94(7):619–27.PubMedPubMedCentral
38.
Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowale T, Igbinoba F, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. Cancer Epidemiol. 2012;36(5):e271–8.CrossRefPubMedPubMedCentral
39.
40.
Ukoli F, Osime U, Akereyeni F, Okunzuwa O, Kittles R, Adams-Campbell L. Prevalence of elevated serum prostate-specific antigen in rural Nigeria. Int J Urol. 2003;10(6):315–22.CrossRefPubMed
41.
Ikuerowo SO, Omisanjo OA, Bioku MJ, Ajala MO, Mordi VP, Esho JO. Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. Pan African Med J. 2013;15:129.CrossRef
42.
Anunobi CC, Akinde OR, Elesha SO, Daramola AO, Tijani KH, Ojewola RW. Prostate diseases in Lagos, Nigeria: a histologic study with tPSA correlation. Niger Postgrad Med J. 2011;18(2):98–104.PubMed
43.
Okolo CA, Akinosun OM, Shittu OB, Olapade-Olaopa EO, Okeke LI, Akang EEU, et al. Correlation of serum PSA and Gleason Score in Nigerian men with prostate cancer. Afr J Urol. 2008;14:15–22.CrossRef
44.
Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume 1-The Analysis of Case–control Studies. Lyon: International Agency for Research on Cancer; 1980.
45.
Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.CrossRefPubMed
46.
Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.CrossRefPubMedPubMedCentral
47.
Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32.CrossRefPubMedPubMedCentral
48.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.CrossRefPubMed
49.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.CrossRefPubMedPubMedCentral
50.
Thompson Jr IM, Leach RJ, Ankerst DP. Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA. 2014;312(10):995–6.CrossRefPubMedPubMedCentral
51.
Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. Nig Q J Hosp Med. 2009;19(3):145–7.PubMed
52.
53.
Taioli E, Flores-Obando RE, Agalliu I, Blanchet P, Bunker CH, Ferrell RE, et al. Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis. 2011;32(9):1361–5.CrossRefPubMedPubMedCentral
Metadata
Title
The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria
Authors
Ilir Agalliu
Akin O Adebiyi
David W Lounsbury
Oluwafemi Popoola
Kola Jinadu
Olukemi Amodu
Suvam Paul
Adebola Adedimeji
Chioma Asuzu
Michael Asuzu
Olufemi J Ogunbiyi
Thomas Rohan
Olayiwola B Shittu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2015
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-015-1754-x

Other articles of this Issue 1/2015

BMC Public Health 1/2015 Go to the issue

Research article

An evaluation of psychological distress and social support of survivors and contacts of Ebola virus disease infection and their relatives in Lagos, Nigeria: a cross sectional study − 2014

Research article

Australian health care providers’ views on opt-out HIV testing

Research article

Knowledge and attitude towards rape and child sexual abuse – a community-based cross-sectional study in Rural Tanzania

Research article

The burden of premature mortality in Poland analysed with the use of standard expected years of life lost

Research article

The need to modify physical activity messages to better speak to older African American women: a pilot study

Research article

The influence of social capital on employers’ use of occupational health services: a qualitative study